# Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

> **NCT02678741** · PHASE1,PHASE2 · COMPLETED · sponsor: **Elios Therapeutics, LLC** · enrollment: 26 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** TLPLDC Vaccine

## Key facts

- **NCT ID:** NCT02678741
- **Lead sponsor:** Elios Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-11-13
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678741, "Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02678741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*